### Covid Vaccines Effectiveness (CoVE)

| Effectiveness of heterologous and booster COVID-19 vaccination     | in 5 |   |
|--|------|---|
| European countries, using a cohort approach in children and adults | with | а |
| full primary COVID-19 vaccination regimen                          |      |   |

Specific Contract No 01 implementing framework contract No EMA/2020/46/TDA/L5.06.

EU PAS Register No: <u>EUPAS47725</u>

Deliverable: D3 - Study report\_ANNEX\_5\_KM curves

Release date: Month 7 – 20 January 2023


Document version: 1.0

### Table of Contents


| Adults (>18 yo) - HOMOLOGOUS vs HETEROLOGOUS PRIMARY VACCINATION            | 3  |
|---|----|
| Non-severe Covid-19 infection (no hospitalized/ICU nor worse)               | 3  |
| Severe Covid-19 infection (hospitalized/ICU or Covid-19 with death)         | 3  |
| Covid-19 with death   |    |
| Adults (>18 yo) - BOOSTER (HOMOLOGOUS) vs NO BOOSTER (among homologous      |    |
| primary vaccinations)   | 4  |
| Non-severe Covid-19 infection (no hospitalized/ICU nor worse)               |    |
| Severe COVID-19 infection (hospitalized/ICU or Covid-19 with death)         |    |
| Covid-19 with death   |    |
| Death for any cause   |    |
| Adults (>18 yo) - BOOSTER (HETEROLOGOUS) vs NO BOOSTER (among homologous    |    |
| primary vaccinations)   | 6  |
| Non-severe Covid-19 infection (no hospitalized/ICU nor worse)               | 6  |
| Severe Covid-19 infection (hospitalized/ICU or Covid-19 with death)         |    |
| COVID-19 with death   |    |
| Death for any cause   |    |
| Adults (>18 yo) - BOOSTER (HETEROLOGOUS) vs NO BOOSTER (among heterologous  |    |
| primary vaccinations)   | 8  |
| Non-severe Covid-19 infection (no hospitalized/ICU nor worse)               | 8  |
| COVID-19 with death   | 8  |
| Death for any cause   | 8  |
| Adolescents (12-17 yo) - HOMOLOGOUS vs HETEROLOGOUS PRIMARY VACCINATION     | 9  |
| Non-severe Covid-19 infection (no hospitalized/ICU nor worse)               | 9  |
| Adolescents (12-17 yo) - BOOSTER (HOMOLOGOUS) vs NO BOOSTER (among homologo |    |
| primary vaccinations)   |    |
| Non-severe Covid-19 infection (no hospitalized/ICU nor worse)               |    |
| Adolescents (12-17 yo) – BOOSTER (HETEROLOGOUS) vs NO BOOSTER (among        |    |
| homologous primary vaccinations)  | 11 |
| Non-severe Covid-19 infection (no hospitalized/ICU nor worse)               |    |
| Children (5-14 yo) - PRIMARY VACCINATION (homologous) vs NO VACCINATION     |    |
| Non-severe Covid-19 infection (no hospitalized/ICU nor worse)               |    |
| Severe Covid-19 infection (hospitalized/ICU or Covid-19 with death)         |    |
|   |    |


### Adults (>18 yo) - HOMOLOGOUS vs HETEROLOGOUS PRIMARY **VACCINATION**

Non-severe Covid-19 infection (no hospitalized/ICU nor worse)




#### Severe Covid-19 infection (hospitalized/ICU or Covid-19 with death)






# Adults (>18 yo) – BOOSTER (HOMOLOGOUS) vs NO BOOSTER (among homologous primary vaccinations)


Non-severe Covid-19 infection (no hospitalized/ICU nor worse)




#### Severe COVID-19 infection (hospitalized/ICU or Covid-19 with death)




#### Covid-19 with death




### Death for any cause






# Adults (>18 yo) – BOOSTER (HETEROLOGOUS) vs NO BOOSTER (among homologous primary vaccinations)


Non-severe Covid-19 infection (no hospitalized/ICU nor worse)




#### Severe Covid-19 infection (hospitalized/ICU or Covid-19 with death)



#### COVID-19 with death




### Death for any cause



### Adults (>18 yo) - BOOSTER (HETEROLOGOUS) vs NO BOOSTER (among heterologous primary vaccinations)

Non-severe Covid-19 infection (no hospitalized/ICU nor worse)




Survival Time In Days Death for any cause

150 200


# Adolescents (12-17 yo) – HOMOLOGOUS vs HETEROLOGOUS PRIMARY VACCINATION

Non-severe Covid-19 infection (no hospitalized/ICU nor worse)




# Adolescents (12-17 yo) – BOOSTER (HOMOLOGOUS) vs NO BOOSTER (among homologous primary vaccinations)


Non-severe Covid-19 infection (no hospitalized/ICU nor worse)



# Adolescents (12-17 yo) – BOOSTER (HETEROLOGOUS) vs NO BOOSTER (among homologous primary vaccinations)


Non-severe Covid-19 infection (no hospitalized/ICU nor worse)





## Children (5-14 yo) - PRIMARY VACCINATION (homologous) vs NO VACCINATION

Non-severe Covid-19 infection (no hospitalized/ICU nor worse)



#### Severe Covid-19 infection (hospitalized/ICU or Covid-19 with death)

